Answers are grounded in this paper and cite their sources.
// Dusten Unruh 1 , Betül Ünlü 2 , Clayton S. Lewis 1 , Xiaoyang Qi 1 , Zhengtao Chu 1 , Robert Sturm 1 , Ryan Keil 1 , Syed A. Ahmad 1 , Timofey Sovershaev 3 , Mariette Adam 4 , Patrick Van Dreden 4 , Barry J. Woodhams 5 , Divya Ramchandani 6 , Georg F. Weber 6 , Janusz W. Rak 7 , Alisa S. Wolberg 8 , Nigel Mackman 8 , Henri H. Versteeg 2 , Vladimir Y. Bogdanov 1 1 College of Medicine, University of Cincinnati, Cincinnati, OH, USA 2 Leiden University Medical Center, Leiden, The Netherlands 3 The Arctic University of Norway, Tromsø, Norway 4 Diagnostica Stago R & D, Gennevilliers, France 5 Haemacon Ltd, Bromley, UK 6 College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA 7 McGill University Health Centre, Montreal Children’s Hospital, Montreal, Canada 8 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Correspondence to: Vladimir Y. Bogdanov, email: vladimir.bogdanov@uc.edu Keywords: pancreatic cancer, tissue factor, alternative splicing, β1 integrins, metastasis Received: August 25, 2015 Accepted: February 13, 2016 Published: March 07, 2016 ABSTRACT Alternatively spliced Tissue Factor (asTF) is a secreted form of Tissue Factor (TF), the trigger of blood coagulation whose expression levels are heightened in several forms of solid cancer, including pancreatic ductal adenocarcinoma (PDAC). asTF binds to β1 integrins on PDAC cells, whereby it promotes tumor growth, metastatic spread, and monocyte recruitment to the stroma. In this study, we determined if targeting asTF in PDAC would significantly impact tumor progression. We here report that a novel inhibitory anti-asTF monoclonal antibody curtails experimental PDAC progression. Moreover, we show that tumor-derived asTF is able to promote PDAC primary growth and spread during early as well as later stages of the disease. This raises the likelihood that asTF may comprise a viable target in early- and late-stage PDAC. In addition, we show that TF expressed by host cells plays a significant role in PDAC spread. Together, our data demonstrate that targeting asTF in PDAC is a novel strategy to stem PDAC progression and spread.
No takes yet. Share an insight, caveat, or question.
Unruh et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: